Converge Bio raises $25M, backed by Bessemer and execs from Meta, OpenAI, Wiz

Converge Bio, a company using generative AI trained on molecular data to accelerate drug development for pharma and biotech, has raised a $25 million oversubscribed Series A round. The funding was led by Bessemer Venture Partners, with participation from TLV Partners, Saras Capital, Vintage Investment Partners, and executives from Meta, OpenAI, and Wiz.

The Boston- and Tel Aviv–based startup trains generative models on DNA, RNA, and protein sequences, integrating them into customer workflows to speed up R&D across stages like target identification and antibody design. Converge has already deployed three discrete AI systems for antibody design, protein yield optimization, and biomarker discovery, emphasizing ready-to-use systems rather than single models.

Since its seed round a year and a half ago, Converge has completed over 40 programs with more than a dozen customers globally and rapidly expanded its team. CEO Dov Gertz noted the industry shift from trial-and-error to data-driven molecular design, asserting that Converge's core technology relies on models trained directly on biological sequences, not just text-based LLMs, to mitigate risks like hallucinations in molecular design.

(Source：TechCrunch)